⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ROIV News
Roivant Sciences Ltd. Common Shares
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
globenewswire.com
IMVT
ROIV
CART
NVS
MRK
REGN
UCB
JNJ
AMGN
ARGX
KYMR
CABA
BMY
BHVN
Form 8-K
sec.gov
ROIV
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
globenewswire.com
ROIV
ROIVW
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
globenewswire.com
ROIV
ROIVW
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
globenewswire.com
ROIV
ROIVW
Form 8-K/A
sec.gov
ROIV
Form 8-K
sec.gov
ROIV
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
globenewswire.com
ABUS
ROIV
MRNA
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
globenewswire.com
ROIVW
ABUS
ROIV
Form 8-K
sec.gov
ROIV